BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28408621)

  • 1. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
    Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
    Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen Initiation After Ductal Carcinoma In Situ.
    Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
    Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
    Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
    Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
    Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
    Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation.
    Punglia RS; Cronin AM; Uno H; Stout NK; Ozanne EM; Greenberg CC; Frank ES; Schrag D
    JAMA Oncol; 2017 Jan; 3(1):101-104. PubMed ID: 27442038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.
    Sprague BL; Vacek PM; Herschorn SD; James TA; Geller BM; Trentham-Dietz A; Stein JL; Weaver DL
    Breast Cancer Res Treat; 2019 Feb; 174(1):227-235. PubMed ID: 30448897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
    Halasz SR; O'Keefe T; Wallace AM; Blair SL
    Breast Cancer Res Treat; 2021 Apr; 186(2):551-559. PubMed ID: 33180236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
    Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L
    Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
    Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
    Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
    Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
    Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
    Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
    Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
    Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
    Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ.
    Greenberg CC; Habel LA; Hughes ME; Nekhlyudov L; Achacoso N; Acton L; Schrag D; Jiang W; Edge S; Weeks JC; Punglia RS
    Ann Surg Oncol; 2014 Nov; 21(12):3766-73. PubMed ID: 24859938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
    Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
    Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
    Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 18. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.
    Virnig BA; Tuttle TM; Shamliyan T; Kane RL
    J Natl Cancer Inst; 2010 Feb; 102(3):170-8. PubMed ID: 20071685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing practices of endocrine therapy for ductal carcinoma
    Chaudhry AT; Koulis TA; Speers C; Olson RA
    Curr Oncol; 2018 Apr; 25(2):133-138. PubMed ID: 29719429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.
    Subhedar P; Olcese C; Patil S; Morrow M; Van Zee KJ
    Ann Surg Oncol; 2015 Oct; 22(10):3273-81. PubMed ID: 26215193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.